Media headlines about Pfizer (NYSE:PFE) have trended somewhat positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pfizer earned a news impact score of 1.86 on their scale. InfoTrie also gave news stories about the biopharmaceutical company an news buzz score of 10 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have impacted Pfizer’s analysis:
- Pfizer: Added Value For A Defensive Pharma Portfolio – Seeking Alpha (seekingalpha.com)
- Stocks To Buy: Is It Time To Buy Or Sell These Large-Cap Stocks? (finance.yahoo.com)
- Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock – Investorplace.com (investorplace.com)
- Google sister-company Verily is teaming with big pharma on clinical trials – CNBC (cnbc.com)
- Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research – Yahoo Finance (finance.yahoo.com)
A number of analysts recently weighed in on PFE shares. ValuEngine lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Citigroup reissued a “neutral” rating and issued a $41.00 price target on shares of Pfizer in a report on Wednesday, February 20th. JPMorgan Chase & Co. set a $46.00 price target on shares of Pfizer and gave the company a “neutral” rating in a report on Tuesday, April 30th. Cantor Fitzgerald reissued a “buy” rating and issued a $53.00 price target on shares of Pfizer in a report on Tuesday, February 19th. Finally, Zacks Investment Research lowered shares of Pfizer from a “hold” rating to a “sell” rating in a report on Thursday, March 28th. Fourteen equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $45.83.
PFE traded up $0.32 during trading on Wednesday, reaching $41.99. 22,893,015 shares of the company’s stock were exchanged, compared to its average volume of 24,386,881. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.27 and a current ratio of 1.54. Pfizer has a fifty-two week low of $35.32 and a fifty-two week high of $46.47. The firm has a market capitalization of $246.87 billion, a PE ratio of 14.00, a P/E/G ratio of 2.40 and a beta of 0.71.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. The firm had revenue of $13.12 billion during the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.77 EPS. Equities analysts forecast that Pfizer will post 2.89 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 10th will be given a dividend of $0.36 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.43%. Pfizer’s dividend payout ratio is 48.00%.
In other news, insider Mikael Dolsten sold 100,471 shares of Pfizer stock in a transaction on Friday, March 1st. The shares were sold at an average price of $43.56, for a total transaction of $4,376,516.76. Following the transaction, the insider now directly owns 390,097 shares of the company’s stock, valued at $16,992,625.32. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Pfizer Inc purchased 50,000 shares of Pfizer stock in a transaction dated Monday, May 13th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 288,726 shares of company stock worth $12,534,617. Insiders own 0.09% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://sundanceherald.com/2019/05/22/pfizer-pfe-given-daily-news-sentiment-score-of-1-86.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: How to read a candlestick chart
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.